(A) Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Antibody. Ipilimumab, a monoclonal antibody directed against CTLA-4, was the first drug that was shown to produce a survival benefit in advanced melanoma [38]. Here, CTLA4 is linked to melanoma.